Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.2K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
1.7K
Cancer Therapies02:49

Cancer Therapies

10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhanced Recovery After Surgery (ERAS) Outcomes After Liver and Pancreas Surgery Based on Regional Perioperative Pain Modalities.

Cureus·2026
Same author

New Paradigms of Cancer Require New Language: A Qualitative Study Exploring Language for Non-Curative Non-Palliative Cancer Surgery.

Journal of surgical oncology·2026
Same author

Dendritic cell redundancy enables priming of anti-tumor CD4<sup>+</sup> T cells in pancreatic cancer.

Cancer cell·2026
Same author

Bayesian sequential learning for prognostication in extremity soft tissue sarcoma (BayeSarc): a retrospective, multicentre cohort study.

The Lancet. Oncology·2026
Same author

In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Preoperative Radiotherapy and Postoperative Complications Among Patients with Primary Retroperitoneal Sarcoma: A Post Hoc Analysis of the EORTC-62092 (STRASS) Phase 3 Randomized Clinical Trial.

Annals of surgery·2026
Same journal

Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.

Oncology (Williston Park, N.Y.)·2026
Same journal

Access to Care and the Affordable Care Act: Why Do Problems Exist 15 Years Later?

Oncology (Williston Park, N.Y.)·2026
Same journal

Synchronous Endometrial and Ovarian Cancers: A Case Study and Literature Review.

Oncology (Williston Park, N.Y.)·2026
Same journal

Perceived Social Support, Anxiety, and Depression Among Women With Breast Cancer.

Oncology (Williston Park, N.Y.)·2026
Same journal

Before Certainty.

Oncology (Williston Park, N.Y.)·2026
Same journal

Adult T-Cell Leukemia/Lymphoma and Epstein-Barr Virus-Positive DLBCL: A Rare Concomitant Association.

Oncology (Williston Park, N.Y.)·2026
See all related articles

Related Experiment Video

Updated: Mar 26, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.4K

Neoadjuvant Therapy for Soft-Tissue Sarcomas.

Mark Fairweather, Emily Keung, Chandrajit P Raut

    Oncology (Williston Park, N.Y.)
    |January 22, 2016
    PubMed
    Summary
    This summary is machine-generated.

    Soft-tissue sarcomas are challenging rare cancers. This review discusses neoadjuvant therapies for soft-tissue sarcomas, exploring their role in local and distant control for improved patient outcomes.

    More Related Videos

    Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
    07:55

    Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

    Published on: April 11, 2018

    15.3K
    Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
    08:04

    Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

    Published on: March 18, 2014

    13.4K

    Related Experiment Videos

    Last Updated: Mar 26, 2026

    A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
    07:15

    A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

    Published on: July 28, 2020

    10.4K
    Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
    07:55

    Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

    Published on: April 11, 2018

    15.3K
    Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
    08:04

    Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

    Published on: March 18, 2014

    13.4K

    Area of Science:

    • Oncology
    • Surgical Oncology
    • Medical Oncology

    Background:

    • Soft-tissue sarcomas are rare, diverse neoplasms presenting therapeutic challenges due to size and proximity to critical structures.
    • Despite complete resection, local and distant recurrence rates remain significant, necessitating advanced treatment strategies.
    • Optimal management requires a multidisciplinary approach involving surgical, medical, and radiation oncologists.

    Purpose of the Study:

    • To review current neoadjuvant treatment options for soft-tissue sarcomas.
    • To discuss the role of neoadjuvant therapy in local and distant control.
    • To highlight the factors influencing neoadjuvant therapy decisions, including tumor biology and location.

    Main Methods:

    • Literature review of current neoadjuvant treatment strategies for soft-tissue sarcomas.
    • Analysis of factors influencing the use and efficacy of neoadjuvant therapies.
    • Discussion of controversies and areas for future research in neoadjuvant treatment.

    Main Results:

    • Neoadjuvant therapies offer potential for local and distant control in soft-tissue sarcomas.
    • Treatment decisions are influenced by histologic subtype, grade, and tumor location.
    • The use of neoadjuvant therapy remains an area of ongoing clinical debate and research.

    Conclusions:

    • Neoadjuvant therapy is a critical component in the multidisciplinary management of soft-tissue sarcomas.
    • Further research is needed to optimize neoadjuvant treatment protocols based on tumor-specific characteristics.
    • Personalized neoadjuvant treatment strategies may improve outcomes for patients with soft-tissue sarcomas.